Hereby, using a nationwide database, we aimed to study whether regular aspirin use is associated with a risk reduction of major adverse cardiovascular and cerebrovascular events (MACCEs) in prostate cancer patients receiving GnRH therapy. This evidence concerns the gene GNRH1 and Familial prostate cancer.